|
|
|
||||||||||
Drug Information Specialty Resident, Drug Information Center, University of Tennessee Health Science Center, Memphis, TN
Assistant Professor, College of Pharmacy, University of Tennessee; Associate Director, Drug Information Center, University of Tennessee Health Science Center
Coordinator, Drug Use Policy, Methodist Healthcare University Hospital; Assistant Professor, College of Pharmacy, University of Tennessee
Reprints: Malia L Moore PharmD, Drug Information Center, University of Tennessee Health Science Center, 875 Monroe Ave., Ste. 109, Memphis, TN 38163-0001, fax 901/448-5419, mmoore31{at}utmem.edu
OBJECTIVE: To review literature describing use of selective serotonin-reuptake inhibitors (SSRIs) in the management of functional impairments associated with autistic disorder.
DATA SOURCES: EMBASE (19803rd quarter of 2003), International Pharmaceutical Abstracts (1970August 2003), and MEDLINE (1966August 2003) were searched. Search terms included autism, autistic disorder, citalopram, fluoxetine, fluvoxamine, paroxetine, selective serotonin-reuptake inhibitors, and sertraline.
DATA SYNTHESIS: Studies and case reports evaluating treatment outcomes associated with the use of SSRIs in managing impairments of autism were reviewed. Multiple SSRI dosing ranges were evaluated in autistic patients of different ages with various functional impairments. No specific SSRI or dose range has been shown to improve a specific autistic symptom although some patients have demonstrated improvements.
CONCLUSIONS: Benefits with SSRIs in treating functional impairments in autism have been observed. Response to therapy and adverse effects are individualized. Current evidence does not support selection of one SSRI over another for any impairment associated with autism.
Key Words: autistic disorder, pervasive developmental disorders, selective serotonin-reuptake inhibitor
Published Online, August 3, 2004. www.theannals.com, DOI 10.1345/aph.1D543
This article has been cited by other articles:
![]() |
B. H. King, E. Hollander, L. Sikich, J. T. McCracken, L. Scahill, J. D. Bregman, C. L. Donnelly, E. Anagnostou, K. Dukes, L. Sullivan, et al. Lack of Efficacy of Citalopram in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior: Citalopram Ineffective in Children With Autism Arch Gen Psychiatry, June 1, 2009; 66(6): 583 - 590. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Myers, C. P. Johnson, and the Council on Children With Disabilities Management of Children With Autism Spectrum Disorders Pediatrics, November 1, 2007; 120(5): 1162 - 1182. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. Wassink, H. C. Hazlett, E. A. Epping, S. Arndt, S. R. Dager, G. D. Schellenberg, G. Dawson, and J. Piven Cerebral Cortical Gray Matter Overgrowth and Functional Variation of the Serotonin Transporter Gene in Autism Arch Gen Psychiatry, June 1, 2007; 64(6): 709 - 717. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M Stachnik and C. Nunn-Thompson Use of Atypical Antipsychotics in the Treatment of Autistic Disorder Ann. Pharmacother., April 1, 2007; 41(4): 626 - 634. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Friedlander, J. A. Yagiela, V. I. Paterno, and M. E. Mahler The neuropathology, medical management and dental implications of autism. J Am Dent Assoc, November 1, 2006; 137(11): 1517 - 1527. [Abstract] [Full Text] [PDF] |
||||